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Medical Marijuana Laws, Traffic Fatalities, 
and Alcohol Consumption 
 
To date, 16 states have passed medical marijuana laws, yet very little is known about their 
effects. Using state-level data, we examine the relationship between medical marijuana laws 
and a variety of outcomes. Legalization of medical marijuana is associated with increased 
use of marijuana among adults, but not among minors. In addition, legalization is associated 
with a nearly 9 percent decrease in traffic fatalities, most likely to due to its impact on alcohol 
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1. INTRODUCTION 
Medical marijuana laws (hereafter MMLs) remove state-level penalties for using, 
possessing and cultivating medical marijuana.  Patients are required to obtain approval or 
certification from a doctor, and doctors who recommend marijuana to their patients are immune 
from prosecution.  MMLs allow patients to designate caregivers, who can buy or grow marijuana 
on their behalf. 
On July 1, 2011 Delaware became the 16th state, along with the District of Columbia, to 
enact a MML.  Six more state legislatures, including those of New York and Illinois, have 
recently considered medical marijuana bills.  If these bills are eventually signed into law, 
approximately 40 percent of the United States population will live in states that permit the use of 
medical marijuana.  
Opponents of medical marijuana tend to focus on the “social issues” surrounding 
substance use.  They argue that marijuana is addictive, serves as a gateway drug, has little 
medicinal value, and leads to criminal activity (Adams 2008; Blankstein 2010).  Another often-
raised argument against legalization is that it encourages the recreational use of marijuana, 
especially by teenagers (Brady et al. 2011; O’Keefe and Earleywine 2011).  Proponents contend 
that marijuana is both efficacious and safe, and can be used to treat the side effects of 
chemotherapy as well as the symptoms of AIDS, multiple sclerosis, epilepsy, glaucoma and 
other serious illnesses.  They cite clinical research showing that marijuana relieves chronic pain, 
nausea, muscle spasms and appetite loss (Eddy 2010; Marmor 1998; Watson et al. 2000), and 
note that neither the link between medical marijuana and youth consumption, nor the link 
between medical marijuana and criminal activity, has been substantiated (Belville 2011; Corry et 
al. 2009; Hoeffel 2011; Lamoureux 2011).   2 
 
This study begins by examining marijuana use in three states that passed a MML in the 
mid-2000s.  Drawing on data collected by the National Survey on Drug Use and Health 
(NSDUH), we find that the passage of a MML was associated with increased marijuana use by 
adults in Montana and Rhode Island, but not by adults in Vermont where, as of June 2011, only 
349 patients were registered.  We find no evidence to support the hypothesis that MMLs are 
related to the use of marijuana by minors.   
 Next, we turn our attention to MMLs and traffic fatalities, the primary relationship of 
interest.  In the United States, traffic fatalities are the leading cause of death among Americans 
ages 5 through 34 (Centers for Disease Control and Prevention 2010).  To our knowledge, there 
has been no previous examination of this relationship.  Data on traffic fatalities at the state level 
are obtained from the Fatality Analysis Reporting System (FARS) for the years 1990-2009.  
Thirteen states enacted a MML during this period.  FARS includes the time of day the traffic 
fatality occurred, the day of the week it occurred, and whether alcohol was involved.  Using this 
information, we contribute to the long-standing debate on whether marijuana and alcohol are 
substitutes or complements.  
Specifically, we find that traffic fatalities fall by nearly 9 percent after the legalization of 
medical marijuana.  However, the effect of MMLs on traffic fatalities involving alcohol appears 
to be larger, and is estimated with more precision, than the effect of MMLs on traffic fatalities 
that did not involve alcohol.  Likewise, we find that the estimated effects of MMLs on fatalities 
at night and on weekends (when alcohol consumption rises) are larger, and are more precise, 
than the estimated effects of MMLs on fatalities during the day and on weekdays.  
Finally, the relationship between MMLs and more direct measures of alcohol 
consumption is examined.  Using data from the Behavioral Risk Factor Surveillance System   3 
 
(BRFSS), we find that MMLs are associated with decreases in the number of drinks consumed, 
especially among 20- through 29-year-olds, providing additional evidence that alcohol is the 
mechanism by which traffic fatalities are reduced.  Using data from the Beer Institute, we find 
that beer sales fall after a MML comes into effect, suggesting that marijuana substitutes for beer, 





2.1. A brief history of medical marijuana  
  Marijuana was introduced in the United States in the early-1600s by Jamestown settlers 
who used the plant in hemp production; hemp cultivation remained a prominent industry until 
the mid-1800s (Deitch 2003).  During the census of 1850, the United States recorded over 8,000 
cannabis plantations of at least 2,000 acres (U.K. Cannabis Campaign 2011).  Throughout this 
period, marijuana was commonly used by physicians and pharmacists to treat a broad spectrum 
of ailments (Pacula et al. 2002).  From 1850 to 1942, marijuana was included in the United 
States Pharmacopoeia, the official list of recognized medicinal drugs (Bilz 1992).   
  In 1913, California passed the first marijuana prohibition law aimed at recreational use 
(Gieringer 1999); by 1936, the remaining 47 states had followed suit (Eddy 2010).  In 1937, The 
Marihuana Tax Act effectively discontinued the use of marijuana for medicinal purposes (Bilz 
1992), and marijuana was classified as a Schedule I drug in 1970.
1  According to the Controlled 
Substances Act (CSA), a Schedule I drug must have a “high potential for abuse,” and “no 
currently accepted medical use in treatment in the United States” (Eddy 2010).
2
                                                           
1 The Marihuana Tax Act imposed a registration tax and required extensive record-keeping, increasing the cost of 
prescribing marijuana as compared to other drugs (Bilz 1992). 
 
2 In addition to marijuana, other current Schedule I substances include heroin, peyote, and psilocybin. 
    4 
 
 In 1996, California passed the Compassionate Use Act, which removed criminal 
penalties for using, possessing and cultivating medical marijuana.  It also provided immunity 
from prosecution to physicians who recommended the use of medical marijuana to their patients.  
Before 1996, a number of states allowed doctors to prescribe marijuana, but this had little 
practical effect because of federal restrictions.
3  Since 1996, 15 other states and the District of 
Columbia have joined California in legalizing the use of medical marijuana (see Table 1), 
although it is still classified as a Schedule I drug by the Federal government.
4
  Laboratory studies have shown that cannabis use impairs driving-related functions such 
as distance perception, reaction time, and hand-eye coordination (Kelly et al. 2004; Sewell et al. 
2009).  However, neither simulator nor driving-course studies provide consistent evidence that 
these impairments to driving-related functions lead to an increased risk of collision (Kelly et al. 
2004; Sewell et al. 2009).  Drivers under the influence of marijuana reduce their velocity, avoid 
risky maneuvers, and increase their “following distances,” suggesting compensatory behavior 
(Kelly et al. 2004; Sewell et al. 2009).  In addition, there appears to be an important learning-by-
doing component to driving under the influence of marijuana: experienced users show 
substantially less functional impairment than infrequent users (Sutton 1983).    
   
 
 
2.2. Studies on substance use and driving   
 
                                                                                                                                                                                           
   
3 Federal regulations prohibit doctors from writing prescriptions for marijuana.  In addition, even if a doctor were to 
illegally prescribe marijuana, it would be against federal law for pharmacies to distribute it.  Doctors in states that 
have legalized medical marijuana avoid violating federal law by recommending marijuana to their patients rather 
than prescribing its use.  Because it is illegal for pharmacies to distribute marijuana, cannabis products intended for 
medicinal use are typically obtained from cooperatives or dispensaries (Eddy 2010). 
 
4 Information on when MMLs were passed was obtained from a recent Congressional Research Services Report by 
Eddy (2010).  Prior to the Obama administration, federal agents raided medical marijuana distributors who violated 
federal laws even if they complied with state statutes.  In 2009, Attorney General Holder stated that the 
administration would discontinue raids on medical marijuana dispensaries (Johnston and Lewis 2009).  Since 2009, 
the search and seizure rates have slowed; however, they have not ceased altogether (CNN 2011; Hamilton 2011; 
L.A. Now 2011).   5 
 
Like marijuana, alcohol impairs driving-related functions such as reaction time and hand-
eye coordination (Kelly et al. 2004; Sewell et al. 2009).  Moreover, there is unequivocal 
evidence from simulator and driving-course studies that alcohol consumption leads to an 
increased risk of collision (Kelly et al. 2004; Sewell et al. 2009).  Even at low doses, drivers 
under the influence of alcohol tend to underestimate the degree to which they are impaired 
(MacDonald et al. 2008; Marczinski et al. 2008; Robbe and O’Hanlon 1993; Sewell et al. 2009), 
drive at faster speeds, and take more risks (Burian et al. 2002; Ronen et al. 2008; Sewell et al. 
2009).  When used in conjunction with marijuana, alcohol appears to have an “additive or even 
multiplicative” effect on driving-related functions (Sewell et al. 2009, p. 186), although there is 
evidence that chronic marijuana users are less impaired by alcohol than infrequent users (Jones 
and Stone 1970; Marks and MacAvoy 1989; Wright and Terry 2002).
5
  A consensus has not been reached with regard to the relationship between marijuana and 
alcohol consumption.  A number of studies have found evidence of complementarity between 
marijuana and alcohol (Pacula 1998; Farrelly et al. 1999; Williams et al. 2004; Yörük and Yörük 
  
 
2.3. The relationship between marijuana and alcohol consumption 
 
  The results discussed in the previous section have different policy implications depending 
upon whether marijuana and alcohol are substitutes or complements.  If they are complements, 
then MMLs could lead to more traffic fatalities as the consumption of marijuana and alcohol 
increase.  If they are substitutes, then MMLs could lead to fewer traffic fatalities as alcohol 
consumption decreases. 
                                                           
5 A large body of research in epidemiology attempts to assess the effects of substance use based on observed THC 
and alcohol levels in the blood of drivers who have been in accidents.  For marijuana, the results have been mixed.  
In contrast, these studies have consistently shown that the likelihood of an accident increases with BAC levels 
(Sewell et al. 2009).  However, it should be noted that this research generally suffers from the problems inherent to 
non-random assignment.   6 
 
2011).  Others, however, lend support to the hypothesis that marijuana and alcohol are 
substitutes.  For instance, Chaloupka and Laixuthai (1997) and Saffer and Chaloupka (1999) 
found that marijuana decriminalization led to decreased alcohol consumption, while DiNardo 
and Lemieux (2001) found that increases in the minimum legal drinking age were positively 
associated with the use of marijuana.   
Two recent studies used a regression discontinuity approach to examine the effect of the 
minimum legal drinking age on marijuana use, but came to different conclusions.  Crost and 
Guerrero (2011) concluded that alcohol and marijuana were substitutes, while Yörük and Yörük 
(2011) concluded that they were complements.  However, according to Yörük and Yörük (2011), 
approximately 75 percent of NLSY97 respondents between the ages of 19 and 22 smoked 
marijuana in the past month.  This figure is inconsistent with evidence on marijuana use by 
young adults available from other studies.
6
Medical marijuana dispensaries are ubiquitous in some parts of Denver, Los Angeles, 
Seattle, and Detroit; in Colorado and Montana, more than two percent of the population is a 




3. MEDICAL MARIJUNA LAWS AND MARIJUANA USE  
7
                                                           
6For instance, using data from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions, 
Compton et al. (2004) found that approximately 11 percent of 18- through 29 year-olds smoked marijuana in the 
past year; Pacula (1998) found that approximately 20 percent of respondents in the NLSY79 admitted to marijuana 
use in the past month; and  DeSimone and Farrelly (2003) reported that approximately 16 percent of 18- through 29-
year-old respondents  in the National Household Surveys on Drug Abuse used marijuana in the past year. 
   
7 Appendix Table 1 presents registry information by state.  According to city and corporate records, Denver has 
more marijuana dispensaries than liquor stores or Starbucks coffee shops (Osher 2010).  
  However, it is not necessarily the case that MMLs have 
led to increased consumption of marijuana; formerly illicit users may have simply become card-
carrying patients.   7 
 
  MMLs afford suppliers to the medicinal market some degree of protection against 
prosecution, and allow patients to buy medical marijuana without fear of being arrested or fined.  
Because it is prohibitively expensive for the government to ensure that all marijuana ostensibly 
grown for the medicinal market ends up in the hands of registered patients (especially in states 
that permit home cultivation), diversion to the illegal market likely occurs.
8  Moreover, the 
majority of MMLs allow patients to register based on medical conditions that cannot be 
objectively confirmed (e.g. chronic pain and nausea).
9  According to recent Arizona registry 
data, only 7 out of 11,186 applications for medical marijuana have been denied approval.
10
  Although there are reasons to expect MMLs to increase the consumption of marijuana, 
the evidence has consisted primarily of popular press reports and anecdotes.
         
11
Funded by the 
  In an effort to fill 
this gap, we draw on data from the National Survey on Drug Use and Health (NSDUH) to 
examine marijuana use in three states that passed MMLs in the mid-2000s. 
Substance Abuse and Mental Health Services Administration (an agency 
of the U.S. Department of Health and Human Services), the NSDUH is an annual, nationally 
                                                           
8 With the exception of Washington D.C., all MMLs enacted during the period 1990-2009 allowed for home 
cultivation.  Since 2009, Delaware and New Jersey have passed MMLs that do not permit home cultivation 
(Marijuana Policy Project 2011). 
 
9 Chronic pain appears to be the most common medical condition among medical marijuana patients (see Appendix 
Table 1). There is anecdotal evidence of “quick-in, quick-out mills,” where physicians provide recommendations for 
a nominal fee (Cochran 2010; Sun 2010). 
 
10 It has been argued that MMLs increase recreational demand, especially among minors, through a destigmatization 
effect.  Bachman et al. (1998) and Pacula et al. (2001) provide evidence that marijuana use increases when 
individuals view it as either socially acceptable or less harmful. Using state-level data for the period 1999-2008 from 
the National Survey on Drug Use and Health (NSDUH), de Silva and Torgler (2011) found that the passage of a 
MML was actually associated with an increased tendency to view marijuana use as risky.  In addition, it is possible 
that MMLs encourage the recreational use of marijuana by increasing the probability of interacting with a person 
who uses it for medicinal purposes (Pacula et al. 2010). 
 
11 To our knowledge, only two previous studies have examined the relationship between MMLs and consumption of 
marijuana.  Gorman and Huber (2007) used data on adult arrestees for the period 1995–2002 from Denver, Los 
Angeles, Portland, San Diego and San Jose. They found little evidence that marijuana consumption among arrestees 
increased as a result of legalization.    8 
 
representative survey of individuals ages 12 and older.  The NSDUH is the best source of 
information on substance use among adults living in the United States, but does not typically 
provide individual-level data with state identifiers to researchers.
12
Specifically, we adopt a difference-in-differences estimation strategy, using neighboring 
states as controls.
 Because the design of the 
NSDUH changed in 1999 (and because data on substance use are not available after 2009), we 
focus on three states that legalized medical marijuana in the mid-2000s: Montana, Rhode Island, 
and Vermont. 
13
Marijuana use among Montana residents (ages 12 and over) increased by 1.7 percentage 
points from the pre-legalization to the post-legalization period.  However, because marijuana use 
in neighboring states increased by 0.8 percentage points, the difference-in-differences estimate is 
0.9 percentage points.
  Table 2 shows marijuana use in the past 30 days, by age group, for Montana 
and its neighboring states.  The “Before MML” period is 1999-2003, and the “After MML” 
period is 2005-2009 (Montana’s MML came into effect on November 2, 2004).   
14
Table 2 provides no evidence that Montana’s MML encouraged minors to smoke 
marijuana.  In contrast, Montana’s MML is associated with a 3.3 percentage point increase in 
marijuana use among 18- through 25-year-olds (or a 19 percent increase from the pre-
 
                                                           
12 Our attempts at obtaining individual-level NSDUH data with state identifiers were politely rebuffed.  Monitoring 
the Future and the Youth Risk Behavior Surveys are important sources of data for researchers interested in the 
determinants of marijuana use, but they do not contain information on adults. 
 
13 If a neighboring state had already passed a MML, then it was not included in the control group. 
 
14 Although the NSDUH does not provide individual-level data with state identifiers, they do provide the sample 
sizes upon which the state-level rates of substance use are based.  We used these sample sizes and the weighted rates 
to calculate approximate standard errors.   
 
   9 
 
legalization mean).  The law is also associated with a 0.6 percentage point increase among older 
adults, but this estimate is not statistically significant. 
The medical marijuana industry is thriving in Montana.  There are currently more than 
27,000 registered patients, representing almost 3 percent of the population.  In contrast, Rhode 
Island legalized medical marijuana on June 3, 2006, and five years later there were 
approximately 3,000 registered patients; Vermont legalized medical marijuana on July 1, 2004, 
and more than six years later there were only 349 registered patients.
15
                                                           
15 It is likely that registry numbers are so low in Vermont because their state law did not allow for dispensaries until 
May 2011 (Marijuana Policy Project 2011). 
  Did marijuana use by the 
residents of Rhode Island and Vermont increase after medical marijuana became legal?  In an 
effort to answer this question, we again turn to state-level data from the NSDUH and a 
difference-in-differences estimation strategy.   
The results are presented in Tables 3 and 4.  There was an increase in adult marijuana use 
after Rhode Island’s MML came into effect.  For instance, marijuana use among 18- through 25-
year-olds increased by 3.5 percentage points from the pre-legalization period to the post-
legalization period, while the use of marijuana among 18- through 25-year-olds in neighboring 
states (Connecticut and Massachusetts) decreased.  There was a 1.4 percentage point increase in 
marijuana use among Vermont residents (ages 12 and over) after legalization, but because 
marijuana use increased by 0.7 percentage points in neighboring states, the difference-in-
differences estimate is a statistically insignificant 0.7 percentage points.  There is no evidence 
that marijuana use among minors increased after legalization in Rhode Island or Vermont. 
 
 
4. MEDICAL MARIJUNA LAWS AND TRAFFIC FATALITIES  
4.1. Data on traffic fatalities   10 
 
  As noted above, we use data from Fatal Accident Report System (FARS) for the period 
1990-2009 to examine the relationship between MMLs and traffic fatalities.  These data are 
collected by the National Highway Traffic Safety Administration, and represent an annual census 
of all fatal injuries suffered in motor vehicle accidents in the United States.  They are obtained 
from a variety of sources, including police crash reports, driver licensing files, vehicle 
registration files, state highway department data, emergency medical services records, medical 
examiner reports, toxicology reports, and death certificates, and contain detailed information on 
the circumstances of each crash and the persons and vehicles involved. 
  Table 5 presents descriptive statistics and definitions for our outcome measures.  
Fatalities Totalst is equal to the number of traffic fatalities per 100,000 licensed drivers in state s 
and year t.
16
The variables Fatalities (BAC > 0)st and Fatalities (BAC ≥ 0.10)st allow us to examine the 
effects of MMLs by alcohol involvement.  Fatalities (BAC > 0)st is equal to the number of fatal 
crashes per 100,000 licensed drivers in state s and year t where at least one driver involved had a 
positive blood alcohol content level.  Fatalities (BAC ≥ 0.10)st is defined analogously, but at least 
one driver had to have a blood alcohol content level greater than or equal to 0.10.  Fatalities (No 
Alcohol)st is equal to the number of fatal crashes per 100,000 licensed drivers where there was no 
reported alcohol involvement.
  As noted by Eisenberg (2003), this variable is policy relevant and is measured with 
little to no error.  
17
                                                           
16 Information on the number of licensed drivers by state was obtained from Highway Statistics, published annually 
by the U.S. Department of Transportation.  Due to missing values, licensed drivers in Indiana and Texas were 
imputed for 2009. 
 
17 The numerator for Fatalities (No Alcohol)st was determined from two sources in the FARS.  First, all drivers 
involved had to have either registered a BAC = 0 or, if BAC information was missing, the police had to report that 
alcohol was not involved.  We also experimented with defining Fatalities (No Alcohol)st based solely on the 
available BAC information.  When this alternative definition was used, the results were similar to those reported 
below.  
    11 
 
  The information in FARS with regard to alcohol involvement is likely measured with 
error (Eisenberg 2003), and there exists the possibility that some states collected information on 
BAC levels more diligently than others.
18
  State-level traffic fatality rates were calculated by sex and age using population data from 
the National Cancer Institute.
  Fortunately, the inclusion of state fixed effects 
eliminates the influence of time-invariant differences in data collection and reporting.  Focusing 
on nighttime and weekend fatal crashes can provide additional insight into the role of alcohol 
and help address the measurement error issue.  As noted by Dee (1999), a substantial proportion 
of fatal crashes on weekends and at night involve alcohol. 
19  There is evidence that the majority of medical marijuana 
patients are male.  In fact, according to state registry data, 75 percent of patients in Arizona, and 
68 percent of patients in Colorado, are male.  There is also evidence that many patients are below 
the age of 40.  Forty-eight percent of registered patients in Montana, and 42 percent of registered 
patients in Arizona, are between the ages of 18 and 40; the average age of registered patients in 
Colorado is 41.
20
  A standard difference-in-differences (DD) regression is used to evaluate the impact of 
MMLs on traffic fatalities.  This approach allows us to exploit the panel nature of our data by 
  To the extent that registered patients below the age of 40 are more likely to use 
medical marijuana recreationally, one might expect heterogeneous effects by age.   
 
4.2. The empirical model 
 
                                                                                                                                                                                           
 
18 Eisenberg (2003) provides an in-depth discussion of measurement error in alcohol-related fatalities in the FARS 
data.   
 
19 These data are available at:  http://seer.cancer.gov/popdata/index.html.  
 
20 Links to state registry data are available at:  http://norml.org/index.cfm?Group_ID=3391.   
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estimating a model that includes both state and year fixed effects.   Specifically, the baseline 
estimating equation is: 
 
(1)    ln(Fatalities Totalst) =  β0 + β1MMLst + Xstβ2 + vs + wt + εst,     
   
where s indexes states and t indexes years.
21
The vector Xst is composed of the controls described in Table 6, and vs and wt are state 
and year fixed effects, respectively.  Previous studies provide evidence that a variety of state-
level policies can impact traffic fatalities.  For instance, graduated driver licensing regulations 
and stricter seatbelt laws are associated with fewer traffic fatalities (Cohen and Einav 2003; Dee 
et al. 2005; Freeman 2007; Carpenter and Stehr 2008).  Other studies have examined the effects 
of speed limits (Ledolter and Chan 1996; Farmer et al. 1999; Greenstone 2002; Dee and Sela 
2003), BAC laws (Dee 2001; Eisenberg 2003), and Zero Tolerance Laws (Carpenter 2004; Liang 
and Huang 2008; Grant 2010).  The relationship between beer taxes and traffic fatalities has also 
received attention from economists (Chaloupka et al. 1991; Ruhm 1996; Dee 1999; Young and 
Likens 2000).
  The variable MMLst indicates whether a MML was 
in effect in state s and year t, and β1, the coefficient of interest, represents the marginal effect of 
legalizing medical marijuana.  In alternative specifications we replace Fatalities Totalst with the 
remaining dependent variables listed in Table 5. 
22
                                                           
21 Dee (2001) used a similar specification to examine the relationship between 0.08 BAC laws and traffic fatalities.  
See also Dee and Sela (2003) and Lovenheim and Steefel (2011).  
 
22 Information on graduated driver licensing laws and seatbelt requirements is available from Dee et al. (2005), 
Cohen and Einav (2003), and the Insurance Institute for Highway Safety (iihs.org).  The FARS accident files were 
used to construct the variable Speed 70. 
 
  In addition to these polices, we include an indicator for marijuana   13 
 
decriminalization, the state unemployment rate, and real per capita income.
 23  Finally, following 
Eisenberg (2003), we control for the vehicle miles driven per licensed driver in the state.
24
The final specification of Table 7 includes state-specific linear time trends.
   
 
4.3. The estimated relationship between MMLs and traffic fatalities 
 
Table 7 presents OLS estimates of the relationship between MMLs and traffic fatalities.  
The regressions are weighted by the population of licensed drivers in state s and year t, and the 
standard errors are corrected for clustering at the state-level (Bertrand et al. 2004). 
In the first column, we present the most basic specification.  Without controls and fixed 
effects, the legalization of medical marijuana is associated with a 22 percent decrease in the 
traffic fatality rate (e
-0.248 – 1 = -0.220).  When state and year fixed effects are included, 
legalization is associated with a 9.7 percent decrease in the fatality rate.  Adding the state-level 
controls decreases the magnitude of the estimated relationship between MMLs and traffic 
fatalities still further.  Legalization is associated with a 7.9 percent decrease in the traffic fatality 
rate. 
25
                                                           
23 Data on decriminalization laws are from Model (1993) and Scott (2010). The possession and use of marijuana is 
not legal in decriminalized states, but expected penalties and fines are lower than those in states without such 
legislation.  For our sample period, however, the decriminalization variable only captures one policy change; 
Nevada decriminalized the use of marijuana in 2001.  The majority of decriminalization laws were passed prior to 
1990. The unemployment and income data are from the Bureau of Labor Statistics and the Bureau of Economic 
Analysis, respectively. 
 
24 Due to missing data, the number of miles driven in Arizona was imputed for 2009. 
 
25 In other words, it includes an interaction between the state dummies and a variable equal to 1 in 1990, 2 in 1991, 3 
in 1993, and so forth.  State-specific linear time trends are included in all subsequent specifications.  
 
  These are 
intended to control for the influence of difficult-to-measure factors at the state level, such as 
sentiment towards marijuana use, that trend smoothly over time.  When state-specific trends are   14 
 
added, the legalization of medical marijuana is still associated with an 8.7 percent decrease in the 
fatality rate.   
  Next, we replace Fatalities Totalst with Fatalities (No Alcohol)st, Fatalities (BAC > 0)st 
and Fatalities (BAC ≥ 0.10)st.  The results are consistent with the hypothesis that MMLs are 
related to traffic fatalities through alcohol consumption (Table 8).  The estimate of β1 is negative 
when fatalities not involving alcohol are considered, but it is relatively small and statistically 
indistinguishable from zero.  In contrast, the legalization of medical marijuana is associated with 
an almost 12 percent decrease in any-BAC fatal crashes per 100,000 licensed drivers, and an 
almost 14 percent decrease in high-BAC fatal crashes per 100,000 licensed drivers.    
  Table 9 shows pre- and post-legalization trends in fatal crashes involving alcohol.  In the 
years preceding legalization, Fatalities (BAC > 0)st and Fatalities (BAC ≥ 0.10)st appear stable, 
suggesting that attitudes towards marijuana did not shift in anticipation of legalization.   
However, 1-2 years after coming into effect, MMLs are associated with a (statistically 
insignificant) 11.0 percent decrease in any-BAC fatal crashes per 100,000 licensed drivers, and a 
13.5 percent decrease in high-BAC fatal crashes per 100,000 licensed drivers.  MMLs are 
associated with even larger reductions in fatal crashes involving alcohol 2-3 years and 3+ years 
post-legalization.  For instance, MMLs are associated with a 15.0 percent decrease in any-BAC 
fatal crashes, and an almost 20 percent reduction in high-BAC fatal crashes, after 3 or more 
years. 
This pattern of results is consistent with state registry data from Colorado, Montana, and 
Rhode Island showing that patient numbers increased slowly in the years immediately after 
legalization, but ramped up quickly thereafter.  For instance, Montana legalized medical 
marijuana in November 2004.  Two years later, only 287 patients were registered; five years   15 
 
later, more than 7,000 patients were registered; and six years later, 27,292 patients were 
registered.
26
  Table 10 provides additional evidence that MMLs decrease traffic fatalities by reducing 
alcohol consumption.  The first two columns of Table 10 show the relationship between MMLs 
and traffic fatalities occurring on weekdays as compared to the weekend, when the consumption 
of alcohol rises (Haines et al. 2003).  Legalization is associated with a 7.8 percent decrease in the 
weekday traffic fatality rate; in comparison, it is associated with a 9.5 percent decrease in the 
weekend traffic fatality rate.  The former estimate is not significant at conventional levels, while 
the latter is significant at the 0.05 level.
   
27
  The last two columns of Table 10 show the relationship between MMLs and traffic 
fatalities occurring during the day as compared to at night, when fatal crashes are more likely to 
involve alcohol (Dee 1999).  Legalization is associated with a 6.8 percent decrease in the 
daytime traffic fatality rate; in comparison, it is associated with a 10.1 percent decrease in the 
nighttime traffic fatality rate.  The former estimate is not significant at conventional levels, but 
the latter is significant at the 0.10 level.
  
28
  Table 11 presents estimates of the relationship between MMLs and traffic fatalities by 
age.  In column 1, the estimate of β1 is negative, but is small in magnitude and statistically 
insignificant.  This is consistent with the evidence discussed above from Montana and Rhode 
Island suggesting that MMLs have little impact on the use of marijuana by minors.  Legalization 
is associated with a 19 percent decrease in the fatality rate of 20- through 29 year-olds, a 16.8 
 
                                                           
26 Patient numbers appear to be growing rapidly in Arizona, which passed the Arizona Medical Marijuana Act on 
November 2, 2010.  Three thousand six hundred and ninety-six patient applications had been approved as of May 
24, 2011;11,133 patient applications had been approved by August 29, 2011.  
 
27 It should be noted, however, that we cannot formally reject the hypothesis that these estimates are equal.   
 
28 It should be noted, however, that we cannot formally reject the hypothesis that these estimates are equal.   
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percent decrease in the fatality rate of 30- through 39-year-olds, and an 11.5 percent decrease in 
the fatality rate of 40- through 49-year-olds.  Although registry data indicate that many medical 
marijuana patients are over the age of 49, there is little evidence that MMLs are associated with 
fatalities among 50- through 59-year-olds or fatalities among individuals 60 years of age and 
older.
29
    Table 12 presents estimates of the relationship between MMLs and traffic fatalities by 
sex.  They provide some evidence that MMLs have a greater impact on fatalities among males as 
compared to females.  Specifically, legalization is associated with a 12.5 percent decrease in the 
male traffic fatality rate as compared to a 9.2 percent decrease in the female fatality rate.  This 
pattern of results is consistent with registry data that shows the majority of medical marijuana 
patients are male.
  This result is consistent with research showing that policies that have been effective at 
increasing younger driver safety are essentially irrelevant for older drivers (Morrisey and 
Grabowski 2005).  
30
                                                           
29 According to state registry data, 37.8 percent and 32.3 percent of registered medical marijuana patients are over 
the age of 50 in Arizona and Montana, respectively. 
 




5. MEDICAL MARIJUNA LAWS, ALCOHOL CONSUMPTION AND SALES 
5.1. Number of Drinks per Month and Binge Drinking  
Administered by state health departments in collaboration with the Centers for Disease 
Control, the Behavioral Risk Factor Surveillance System (BRFSS) is designed to measure 
“behavioral risk factors” for the adult population (18 years of age or older).  Approximately 
350,000 individuals are surveyed by phone every year.  Among the questions asked are:    17 
 
1.  Have you had any beer, wine, wine coolers, cocktails, or liquor during the past          
month? 
2.  During the past month, how many days per week or per month did you drink any 
alcoholic beverages, on the average? 
3.  On days when you drink, about how many drinks do you drink on average? 
 
Using the answers to these questions, we constructed Number of Drinks, equal to the mean 
number of drinks consumed among residents of state s in year t.  In addition, the BRFSS asked, 
about binge drinking.
31
where Xst  is a vector of controls.
  Using the answers to this question, we constructed Binge Drinking, 
equal to the proportion of respondents in state s and year t who engaged in binge drinking in the 
month prior to being interviewed.   
  The top panel of Table 13 presents estimates of the following equation for the period 
1990-2009: 
 
(2)        ln(Number of Drinksst) = π0 + π1MMLst + Xstπ2 + vs + wt + Trends + εst, 
 
32
                                                           
31 Specifically, the BRFSS asks, “Considering all types of alcoholic beverages, how many times during the past 30 
days did you have X or more drinks on an occasion?”, where X is five for male respondents and 4 for female 
respondents. 
32 The vector Xst includes the controls listed in Table 6 with the following exceptions:  Miles driven, GDL, Primary 
seatbelt, Secondary seatbelt, and Speed 70.  We also control for the relevant age- or sex-specific population. 
  The bottom panel presents estimates of (2) replacing Number 
of Drinks with Binge Drinking.  The results are consistent with the hypothesis that marijuana and 
alcohol are substitutes.  The legalization of medical marijuana is associated with a 1.51 reduction 
in the mean number of drinks consumed per month by males, a 0.65 reduction in the mean 
number of drinks consumed by females, and a 0.007 reduction in the proportion of female binge   18 
 
drinkers.  Although the estimates of π1 are negative for every age group, the estimated 
relationship between MMLs and drinking is strongest among 20- through 29-year-olds.    
 
5.2. Alcohol Sales 
Data from the alcohol industry is collected by the Beer Institute and published annually in 
the Brewers Almanac.  State-level data on per capita beer sales (in gallons) are available for the 
period 1990-2009.  Data on wine and spirits sales (in gallons) are available for the period 1994-
2009.  Using these data, we estimate the following equation: 
 
(3)        ln(Salesst) = ∂0 + ∂1MMLst + Xst∂2 + vs + wt + Trends + εst, 
 
where Xst  is a vector of controls.
33  Again, the results are consistent with the hypothesis that 
marijuana and alcohol are substitutes (Table 14).  The legalization of medical marijuana is 
associated with a 5.3 percent reduction in beer sales, the most popular beverage among 18- 
through 29-year-olds during the period under study (Jones 2008).  Legalization is negatively 
related to wine and spirit sales, but the estimates are not statistically significant at conventional 
levels.
34
 To date, 16 states and the District of Columbia have legalized medical marijuana.  




                                                           
33 The vector Xst includes the controls listed in Table 6 with the following exceptions:  Miles driven, GDL, Primary 
seatbelt, Secondary seatbelt, and Speed 70.   
34 These results help explain why The California Beer & Beverage Distributors donated $10,000 to Public Safety 
First, a committee organized to oppose a recent California initiative legalizing marijuana (Grim 2010).    19 
 
of “making marijuana legally available for doctors to prescribe in order to reduce pain and 
suffering” (Mendes 2010).   
Although popular, medical marijuana laws have received minimal scrutiny from 
researchers.  In fact, next to nothing is known about their impact on outcomes of interest to 
policymakers, social scientists, advocates, and opponents.    
  The current study draws on data from a variety of sources to explore the effects of 
legalizing medical marijuana.  Using data from the National Survey on Drug Use and Health 
(NSDUH), we find that the use of marijuana by adults in Montana and Rhode Island increased 
after medical marijuana was legalized.  Although opponents of legalization argue that it 
encourages recreational use among teenagers (Brady et al. 2011; O’Keefe and Earleywine 2011), 
we find no evidence that the use of marijuana by minors increased.   
Using data from the Fatality Analysis Reporting System (FARS) for the period 1990-
2009, we find that traffic fatalities fall by nearly 9 percent after the legalization of medical 
marijuana.  This effect is comparable in magnitude to those found by economists using the FARS 
data to examine other policies.  For instance, Dee (1999) found that increasing the minimum 
legal drinking age to 21 reduces fatalities by approximately 9 percent; Carpenter and Stehr 
(2008) found that mandatory seatbelt laws decrease traffic fatalities among 14- through 18-year-
olds by approximately 8 percent. 
Why does legalizing medical marijuana reduce traffic fatalities?  Alcohol consumption 
appears to play a key role. The legalization of medical marijuana is associated with a 6.4 percent 
decrease in fatal crashes that did not involve alcohol, but this estimate is not statistically 
significant at conventional levels.  In comparison, the legalization of medical marijuana is 
associated with an almost 12 percent decrease in any-BAC fatal crashes per 100,000 licensed   20 
 
drivers, and an almost 14 percent decrease in high-BAC fatal crashes per 100,000 licensed 
drivers.   
The negative relationship between legalization of medical marijuana and traffic fatalities 
involving alcohol is consistent with the hypothesis that marijuana and alcohol are substitutes.  In 
order to explore this hypothesis further, we examine the relationship between medical marijuana 
laws and alcohol consumption using data from the Behavioral Risk Factor Surveillance System 
and The Brewer’s Almanac.  We find that the legalization of medical marijuana is associated 
with decreased alcohol consumption, especially by 20- through 29-year-olds.  In addition, we 
find that legalization is associated with decreased beer sales, the most popular alcoholic beverage 
among young adults (Jones 2008).   
Evidence from simulator and driving course studies provides a simple explanation for 
why substituting marijuana for alcohol may lead to fewer traffic fatalities.  These studies show 
that alcohol consumption leads to an increased risk of collision (Kelly et al. 2004; Sewell et al. 
2009).  Even at low doses, drivers under the influence of alcohol tend to underestimate the 
degree to which they are impaired (MacDonald et al. 2008; Marczinski et al. 2008; Robbe and 
O’Hanlon 1993; Sewell et al. 2009), drive at faster speeds, and take more risks (Burian et al. 
2002; Ronen et al. 2008; Sewell et al. 2009).  In contrast, simulator and driving course studies 
provide only limited evidence that driving under the influence of marijuana leads to an increased 
risk of collision, perhaps as a result of compensatory driver behavior (Kelly et al. 2004; Sewell et 
al. 2009).   
However, because other mechanisms cannot be ruled out, the negative relationship 
between medical marijuana laws and alcohol-related traffic fatalities does not necessarily imply 
that driving under the influence of marijuana is safer than driving under the influence of alcohol.    21 
 
For instance it is possible that legalizing medical marijuana reduces traffic fatalities though its 
effect on substance use in public.  Alcohol is often consumed in restaurants and bars, while many 
states prohibit the use of medical marijuana in public.
35 Even where it is not explicitly 




  If marijuana consumption typically takes place at home, then designating a 
driver for the trip back from a restaurant or bar becomes unnecessary, and legalization could 
reduce traffic fatalities even if driving under the influence of marijuana is every bit as dangerous 
as driving under the influence of alcohol.     
Finally, an important caveat deserves mention.  Our classification of states into those that 
allow the use of medical marijuana and those that prohibit its use does not capture potentially 
important factors such as whether formal registration with the state is compulsory or voluntary, 
what types of ailments are covered, and whether an official dispensary system is in place.  While 
measuring these differences and their impact is beyond the scope of this study, future research 





                                                           
35 For instance, in Colorado “the medical use of marijuana in plain view of, or in a place open to, the general public” 
is prohibited; in Connecticut, the smoking of marijuana is prohibited in “any public place;” in Oregon engaging “in 
the medical use of marijuana in a public place” is prohibited; and in Washington, it is a misdemeanor “to use or 
display medical marijuana in a manner or place which is open to the view of the general public.” Although Montana 
law prohibits the use of medical marijuana in parks, schools, public beaches and correctional facilities, it does not 
explicitly prohibit its use in other public places.  
 
36 See, for instance, Whitnell (2008), Adams (2010), Moore (2010), and Ricker (2010).   22 
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                        Table 1.  Medical Marijuana Laws, 1990-2009                   
 
__________________________________________      Effective date    
Alaska                   March 4, 1999 
California                  November 6, 1996 
Colorado                  June 1, 2001 
Hawaii                   December 28, 2000 
Maine                   December 22, 1999 
Michigan                  December 4, 2008 
Montana                   November 2, 2004 
Nevada                  October 1, 2001 
New Mexico                  July 1, 2007 
Oregon                  December 3, 1998 
Rhode Island                  January 3, 2006 
Vermont                  July 1, 2004 
Washington                  November 3, 1998   
 
Notes:  Arizona, D.C., Delaware, and New Jersey have passed medical marijuana laws since 2009.  Source: Eddy 
(2010). 
          Table 2.  Difference-in-Differences Estimates  
                         of the Effect of Montana’s MML on Marijuana Use___                              
 
           (1)        (2) 
                                     Past Month Usage          Past Month Usage    
                  MT                 ID, ND, SD and WY            (1) – (2)   
All ages 
Before MML      0.069      0.046      0.023*** 
        (0.004)     (0.002)     (0.004) 
After MML      0.086      0.054      0.032*** 
        (0.004)     (0.002)     (0.004) 
Within-state difference   0.017**    0.008***    0.009* 
(row 2 – row 1)    (0.006)     (0.002)     (0.005) 
 
Ages 12 to 17 
Before MML      0.109      0.073      0.036*** 
        (0.008)     (0.003)     (0.008) 
After MML      0.094      0.064      0.031*** 
        (0.007)     (0.003)     (0.007) 
Within-state difference  -0.015     -0.010**    -0.005 
(row 2 – row 1)    (0.011)     (0.005)     (0.011) 
 
Ages 18 to 25 
Before MML      0.178      0.127      0.051*** 
        (0.010)     (0.004)     (0.010) 
After MML      0.224      0.139      0.084*** 
        (0.011)     (0.004)     (0.010) 
Within-state difference  0.045**    0.012**    0.033** 
(row 2 – row 1)    (0.014)     (0.006)     (0.014) 
 
Ages 26 and older 
Before MML      0.044      0.025      0.019*** 
        (0.005)     (0.002)     (0.005) 
After MML      0.062      0.036      0.026*** 
        (0.006)     (0.002)     (0.006) 
Within-state difference  0.017**    0.011***    0.006 
(row 2 – row 1)    (0.008)     (0.003)     (0.008)      
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Based on state-level estimates from the National Surveys on Drug Use and Health (NSDUH), provided by 
the Substance Abuse and Mental Health Services Administration (SAMHSA).  Standard errors (in parentheses) are 
approximated using weighted means and raw sample sizes provided by the NSDUH.  The “Before MML” period is 
1999-2003; the “After MML” period is 2005-2009 (Montana’s MML came into effect on November 2, 2004).   
 
      
 
 
    
    Table 3.  Difference-in-Differences Estimates 
                        of the Effect of Rhode Island’s MML on Marijuana Use              
         
                                                   (1)        (2)  
          Past Month Usage       Past Month Usage  
           RI            CT and MA             (1) – (2)   
All ages 
Before MML      0.083      0.074      0.009** 
        (0.004)     (0.002)     (0.004) 
After MML      0.106      0.072      0.034*** 
        (0.006)     (0.003)     (0.006) 
Within-state difference   0.023***    -0.002     0.025*** 
(row 2 – row 1)    (0.007)     (0.004)     (0.008) 
 
Ages 12 to 17 
Before MML      0.107      0.103      0.004 
        (0.007)     (0.005)     (0.008) 
After MML      0.093      0.082      0.011 
        (0.010)     (0.007)     (0.012) 
Within-state difference  -0.013     -0.021**    0.008 
(row 2 – row 1)    (0.012)     (0.008)     (0.014) 
 
Ages 18 to 25 
Before MML      0.257      0.236      0.021* 
        (0.010)     (0.007)     (0.011) 
After MML      0.293      0.218      0.075*** 
        (0.016)     (0.009)     (0.018) 
Within-state difference  0.035**    -0.019     0.054*** 
(row 2 – row 1)    (0.018)     (0.012)     (0.021) 
 
Ages 26 and older 
Before MML      0.050      0.045      0.005 
        (0.005)     (0.003)     (0.006) 
After MML      0.073      0.046      0.027*** 
        (0.009)     (0.005)     (0.009) 
Within-state difference  0.022**    0.001      0.022** 
 (row 2 – row 1)    (0.009)     (0.006)     (0.011) 
                           
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Based on state-level estimates from the National Surveys on Drug Use and Health (NSDUH), provided by 
the Substance Abuse and Mental Health Services Administration (SAMHSA).  Standard errors are in parentheses.  
The “Before MML” period is 1999-2005; the “After MML” period is 2007-2009 (Rhode Island’s MML came into 
effect on January 3, 2006). 
 
 
    
   Table 4.  Difference-in-Differences Estimates 
                                of the Effect of Vermont’s MML on Marijuana Use                       
(1)    (2)          
                Past Month Usage       Past Month Usage 
        VT         MA, NH and NY    (1) – (2)   
All ages 
Before MML      0.087      0.068      0.019*** 
        (0.004)     (0.002)     (0.004) 
After MML      0.101      0.075      0.026*** 
        (0.005)     (0.002)     (0.004) 
Within-state difference   0.014**    0.007***    0.007 
(row 2 – row 1)    (0.006)     (0.002)     (0.005) 
 
Ages 12 to 17 
Before MML      0.122      0.092      0.031*** 
        (0.008)     (0.003)     (0.008) 
After MML      0.103      0.082      0.021*** 
        (0.008)     (0.003)     (0.008) 
Within-state difference  -0.019*    -0.009**    -0.010 
(row 2 – row 1)    (0.012)     (0.004)     (0.011) 
 
Ages 18 to 25 
Before MML      0.268      0.210      0.058*** 
        (0.011)     (0.004)     (0.011) 
After MML      0.293      0.224      0.069*** 
        (0.012)     (0.004)     (0.012) 
Within-state difference  0.025      0.014**    0.011 
(row 2 – row 1)    (0.016)     (0.006)     (0.016) 
 
Ages 26 and older 
Before MML      0.053      0.042      0.011* 
        (0.006)     (0.002)     (0.006) 
After MML      0.069      0.049      0.021*** 
        (0.007)     (0.002)     (0.006) 
Within-state difference  0.016*     0.007**    0.010 
(row 2 – row 1)    (0.009)     (0.003)     (0.008) 
                           
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Based on state-level estimates from the National Surveys on Drug Use and Health (NSDUH), provided by 
the Substance Abuse and Mental Health Services Administration (SAMHSA).  Standard errors are in parentheses.  
The “Before MML” period is 1999-2003; the “After MML” period is 2005-2009 (Vermont’s MML came into effect 




    
  Table 5.  Descriptive Statistics for FARS Analysis (Dependent Variables)     
 
Variable      Mean (SD)                      Description         
Fatalities Total             21.95 (7.09)              Number of fatalities per 100,000 licensed        
                                                                        drivers 
             
Fatalities                 5.28 (2.16)    Number of any-BAC (>0.00) fatal crashes per 
(BAC > 0)                    100,000 licensed drivers  
 
Fatalities                 4.17 (1.79)    Number of high-BAC (≥0.10) fatal crashes per 
(BAC ≥ 0.10)          100,000 licensed drivers 
     
Fatalities                      13.15 (4.25)              Number of fatal crashes with no indication 
(No Alcohol)                                                   of alcohol use per 100,000 licensed drivers 
                                                                        
Variable      Mean (SD)                      Denominator         
Fatalities,      25.20 (9.53)    per 100,000 15- through 19-year-olds     
15-19 year-olds         
             
Fatalities,               23.96 (8.37)             per 100,000 20- through 29-year-olds 
20-29 year-olds           
 
Fatalities,                      15.63 (6.48)              per 100,000 30- through 39-year-olds 
30-39 year-olds        
             
Fatalities,                      14.15 (5.63)              per 100,000 40- through 49-year-olds 
40-49 year-olds         
 
Fatalities,                13.36 (4.94)              per 100,000 50- through 59-year-olds 
50-59 year-olds       
             
Fatalities,                      17.68 (5.23)              per 100,000 60-year-olds and above 
60 plus                                                              
 
Fatalities males   20.78 (7.12)    per 100,000 males 
                                                                       
Fatalities females     9.18 (3.27)                 per 100,000 females 
                                       
Fatalities weekends    9.38 (3.20)    per 100,000 licensed drivers 
             
Fatalities weekdays    12.52 (4.02)    per 100,000 licensed drivers 
 
Fatalities nighttime    11.17 (3.68)    per 100,000 licensed drivers 
 
Fatalities daytime    10.60 (3.64)    per 100,000 licensed drivers______________   
Notes:  Means are based on the FARS state-level panel for 1990-2009.  The natural log of these rates is used in the 
regression analyses.    
  Table 6.  Descriptive Statistics for FARS Analysis (Independent Variables)     
 
Variable    Mean (SD)    Description             
MML
a     0.122 (0.325)    = 1 if a state had a medical marijuana law in a given 
            year, = 0 otherwise 
Unemployment   5.65 (1.64)    State unemployment rate 
Income     10.26 (0.16)    Natural logarithm of state real income per capita  
            (2000 dollars) 
Miles driven    14.12 (2.05)    Vehicle miles driven per licensed driver 
            (thousands of miles) 
Decriminalized
a  0.316 (0.465)    = 1 if a state had a marijuana decriminalization law  
            in a given year, = 0 otherwise 
GDL
a      0.501 (0.493)    = 1 if a state had a graduated driver licensing law  
            with an intermediate phase in a given year, = 0 
            otherwise 
Primary seatbelt
a  0.430 (0.490)    = 1 if a state had a primary seatbelt law in a given 
            year, = 0 otherwise 
Secondary seatbelt
a  0.547 (0.492)    = 1 if a state had a secondary seatbelt law in a given 
            year, = 0 otherwise 
BAC 0.08
a    0.566 (0.487)    = 1 if a state had a .08 BAC law in a given year, = 0 
            otherwise 
ALR
a      0.723 (0.444)    = 1 if a state had an administrative license  
            revocation law in a given law, = 0 otherwise 
Zero Tolerance
a  0.752 (0.424)    = 1 if a state had a “Zero Tolerance” drunk  
            driving law in a given year, = 0 otherwise 
Beer tax    0.252 (0.215)    Real beer tax (2000 dollars) 
Speed 70    0.456 (0.498)    = 1 if a state had a speed limit of 70 mph or  
            greater in a given year, = 0 otherwise      
 













    
                         Table 7.  Traffic Fatalities and Medical Marijuana Laws: Baseline Results               
     (1)        (2)        (3)        (4)       
____________________    Fatalities Total           Fatalities Total         Fatalities Total           Fatalities Total   
 
MML                 -0.248***            -0.102***             -0.082***            -0.091* 
        (0.062)     (0.021)     (0.020)             (0.047) 
 
N        1020      1020      1020      1020 
R
2        0.061      0.950      0.964      0.975 
 
Year FE      No       Yes      Yes      Yes 
State FE      No       Yes      Yes      Yes 
Covariates      No       No      Yes      Yes 
State-specific trends    No       No       No      Yes     
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural log of total fatalities  
per 100,000 licensed drivers; the covariates are listed in Table 6.  Regressions are weighted using number of licensed drivers in state s and  














    
  Table 8.  Traffic Fatalities and Medical Marijuana Laws: The Role of Alcohol   
         (1)       (2)        (3) 
_____________ __Fatalities (No Alcohol)     Fatalities (BAC > 0)     Fatalities (BAC ≥ 0.10)   
 
MML                 -0.066               -0.127*              -0.150* 
        (0.045)     (0.069)     (0.080) 
 
N        1020      1019      1019 
R
2        0.960      0.888      0.890 
 
Year FE      Yes      Yes      Yes 
State FE      Yes      Yes      Yes 
Covariates      Yes      Yes      Yes 
State-specific trends    Yes      Yes      Yes       
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural 
log of estimated fatal crashes per 100,000 licensed drivers; the covariates are listed in Table 6.  Regressions are 
weighted using number of licensed drivers in state s and year t.   Standard errors, corrected for clustering at the state 



























    
  Table 9.  Traffic Fatalities and Medical Marijuana Laws: The Timing of Laws   
            (1)          (2) 
__________________     Fatalities (BAC > 0)           Fatalities (BAC ≥ 0.10)     
 
2-3 years before MML    0.009        -0.001 
          (0.036)       (0.044) 
1-2 years before MML    0.025        0.017 
          (0.058)       (0.056) 
0-1 year before MML     -0.036       -0.073 
          (0.059)       (0.058) 
Year of law change      -0.004       -0.033 
          (0.055)       (0.060) 
0-1 year after MML      -0.084       -0.119 
          (0.078)       (0.090) 
1-2 years after MML      -0.117                -0.145* 
          (0.073)       (0.079) 
2-3 years after MML               -0.228**               -0.282*** 
          (0.086)       (0.096) 
3+ years after MML      -0.162*               -0.221** 
          (0.088)       (0.094) 
 
p-value: joint significance of lags  0.060*       0.044** 
 
N          1019        1019 
R
2          0.889        0.891 
 
Year FE        Yes        Yes 
State FE        Yes        Yes 
Covariates        Yes        Yes 
State-specific trends      Yes        Yes         
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural 
log of estimated fatal crashes per 100,000 licensed drivers; the covariates are listed in Table 6.  The omitted category 
is 3+ years before MML.  Regressions are weighted using the number of licensed drivers in state s and year t.  











    
                Table 10.  Traffic Fatalities and Medical Marijuana Laws by Day and Time                            
                 (1)              (2)           (3)          (4) 
__________           Fatalities weekdays    Fatalities weekend    Fatalities day     Fatalities night  
 
MML                 -0.081         -0.100**         -0.070                  -0.106* 
                 (0.053)         (0.043)           (0.046)                 (0.054) 
 
N                   1020           1020        1020           1020 
R
2                  0.964           0.956         0.964                    0.960 
 
Year FE                Yes        Yes        Yes        Yes 
State FE            Yes        Yes        Yes        Yes 
Covariates           Yes        Yes        Yes        Yes 
State-specific trends      Yes        Yes        Yes        Yes     
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural  
log of fatalities per 100,000 licensed drivers; the covariates are listed in Table 6.  Regressions are weighted using 











    
                                             Table 11.  Traffic Fatalities and Medical Marijuana Laws by Age                       
                (1)          (2)         (3)            (4)           (5)           (6) 
_________________Fatalities 15-19   Fatalities 20-29    Fatalities 30-39      Fatalities 40-49   Fatalities 50-59     Fatalities 60 plus 
 
MML                -0.041          -0.211***             -0.184**         -0.122**         -0.040           -0.064 
              (0.067)       (0.053)       (0.079)       (0.053)       (0.038)       (0.044) 
 
N              1020        1020        1020        1020        1020        1020 
R
2              0.912        0.942        0.942        0.940        0.895        0.915 
 
Year FE          Yes        Yes        Yes        Yes        Yes        Yes 
State FE          Yes        Yes        Yes        Yes        Yes        Yes 
Covariates         Yes        Yes        Yes        Yes        Yes        Yes 
State-specific trends    Yes        Yes        Yes        Yes        Yes        Yes       
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural log of fatalities per 100,000 population; the 
covariates are listed in Table 6.  Regressions are weighted using the relevant state-by-age populations.  Standard errors, corrected for clustering at the state level, 












    
  Table 12. Traffic Fatalities and Medical Marijuana Laws by Sex       
            (1)          (2) 
_________________         Fatalities males        Fatalities females       
 
MML                  -0.133**              -0.097* 
                   (0.052)                (0.054) 
 
N          1020        1020 
R
2          0.975        0.959 
 
Year FE        Yes        Yes 
State FE        Yes        Yes 
Covariates        Yes        Yes 
State-specific trends      Yes        Yes         
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variable is equal to the natural 
log of fatalities per 100,000 population; the covariates are listed in Table 6.  Regressions are weighted using the 
























    
_____      Table 13.  Number of Drinks, Binge Drinking and Medical Marijuana Laws: Evidence from the BRFSS           
                    (1)           (2)          (3)      (4)          (5)       (6)      (7)     (8) 
                                             Males    Females  15-19    20-29    30-39    40-49    50-59    60 + 
                              yr.-olds  yr.-olds  yr.-olds  yr.-olds  yr.-olds  yr.-olds         
Number of Drinks 
MML                -1.514*  -0.648*** -1.389   -3.788*** -0.507   -0.707   -0.418   -0.267 
                  (0.772)   (0.234)   (1.082)   (1.416)   (0.774)   (0.632)   (0.458)   (0.498) 
 
Mean # Drinks, MML = 0       16.08    5.463    10.68    15.03    11.06    10.66    9.66    7.101 
N                  852    852    852    852    852    852    852    852 
R
2                  0.768    0.898    0.353    0.638    0.645    0.708    0.786    0.885           
Binge Drinking 
MML                -0.002   -0.007*  -0.000   -0.010   0.002    -0.010   0.001    -0.003 
                  (0.009)   (0.004)   (0.027)   (0.016)   (0.009)   (0.009)   (0.005)   (0.003) 
 
Mean Incidence of Binge 
Drinking, MML = 0        0.220    0.079    0.208    0.280    0.186    0.139    0.094    0.037 
N                  855    855    855    855    855    855    855    855 
R
2                  0.834    0.895    0.528    0.825    0.795    0.815    0.778    0.774           
 
Year FE              Yes    Yes    Yes    Yes    Yes    Yes    Yes    Yes 
State FE               Yes    Yes    Yes    Yes    Yes    Yes    Yes    Yes 
Covariates              Yes    Yes    Yes    Yes    Yes    Yes    Yes    Yes 
State-specific trends         Yes    Yes    Yes    Yes    Yes    Yes    Yes    Yes           
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  Each column represents the results from a separate regression.  The dependent variables are the mean number of drinks consumed in the past 30 days and 
the rate of binge drinking in the past 30 days in state s and year t, and are based on information collected from the Behavioral Risk Factor Surveillance System 
(BRFSS) for the period 1990-2009.  Controls include the state unemployment rate, per capita income, the relevant population size (e.g., the number of males in 
state s and year t), the state beer tax, and indicators for marijuana decriminalization, BAC 0.08, administrative license revocation, and Zero Tolerance.  




    
  Table 14.  Per Capita Alcohol Sales and Medical Marijuana Laws       
           (1)         (2)         (3) 
                                             State-level per           State-level per            State-level per     
             capita beer sales         capita wine sales        capita spirits sales 
                (1990-2009)            (1994-2009)           (1994-2009)     
 
MML                  -0.054***             -0.012               -0.002 
        (0.018)     (0.014)     (0.012) 
 
N        1020      816      816 
R
2        0.983      0.990      0.990 
 
Year FE      Yes      Yes      Yes 
State FE      Yes      Yes      Yes 
State covariates    Yes      Yes      Yes 
State-specific trends    Yes      Yes      Yes       
*Statistically significant at 10% level; **at 5% level; ***at 1% level. 
 
Notes:  The dependent variable is equal to the natural log of per capita sales (measured in gallons) and is based on 
data from the Brewers Almanac, published by the Beer Institute.  Controls include the state unemployment rate, per 
capita income, the state beer tax, and indicators for marijuana decriminalization, BAC 0.08, administrative license 
revocation, and Zero Tolerance.  Regressions are weighted using state population.  Standard errors, corrected for 

























    
                    Appendix Table 1.  Registry Information by State, 2011___                   __    
      Number of  
      registered  Chronic      Average  18-40 years 
      patients  pain (%)  Male (%)   age    of age (%)   
Alaska     380
a    …    …    …    … 
   
Arizona    11,133   86    75    …    42 
 
California    1,250,000
b  …    …    …    … 
 
Colorado    127,816  94    68    41    … 
 
Hawaii     8,000
c   …    …    …    … 
 
Maine     796    …    …    …    … 
 
Michigan    105,458  …    …    …    … 
 
Montana     26,492   86    …    41    48 
 
New Mexico    3,981    24    …    …    … 
 
Oregon    49,220   65    …    …    … 
 
Rhode Island    3,073    20    …    …    … 
 
Vermont    349
d    …    …    …    … 
 
Washington    100,000
e  …    …    …    …                        
aBased on a communication between NORML and the Alaska Bureau of Vital Statistics. 
bEstimated by NORML. 
cEstimated by the Drug Policy Forum of Hawaii. 
dBased on a communication between NORML and the Vermont Criminal Information Center. 
eEstimated by NORML. 
  
Notes: Unless otherwise indicated, the information in this table was obtained from official state registry data.  Links 
to state registry data are available at:  http://norml.org/index.cfm?Group_ID=3391. 
 
 
 
 